NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK investor conferences, and online events which engage an estimated 12 million investors globally each year.
This week’s momentum leaders with accelerating news flow include: NexTech AR (OTC: NEXCF) (CSE: NTAR), PharmaDrug (OTC: LMLLF) (CSE: PHRX), ORAGIN Foods (OTC: OGGFF) (TSX.V: OG), and Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA). Wall Street Reporter’s NEXT SUPER STOCK conferences feature disruptive innovation leaders with +10X upside potential. These emerging growth companies are pursuing multi-billion dollar market opportunities, and are at a key inflection point in their growth trajectory - with multiple catalysts in-place to drive transformational growth, and shareholder value. This selective focus on ultra high-potential leaders, has already delivered nine 10X to 50X wins, along with numerous triple digit wins, in the past 20 months.
Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, M.D.: “Nova’s Psilocybin-based Therapeutics Showing Vast Potential for Autism and Other Neuroinflammatory Disorders”
https://www.wallstreetreporter.com/2022/03/25/next-super-stock-nova-mentis-life-sciences-otc-nmlsf-billions-opportunity-w-autism-psilocybin/
ORAGIN Foods (OTC: OGGFF) (TSX.V: OG) CEO Matt Lurie: “Ready to Scale with Plant-Based Brands and Next Gen Organic Retailing” https://www.wallstreetreporter.com/2022/03/01/oragin-foods-otc-oggff-tsx-og-unleashes-30x-upside-potential/
PharmaDrug (OTC: LMLLF) (CSE: PHRX) CEO Dan Cohen: “Advancing Drug Pipeline Addressing Billion Dollar Markets”
https://www.wallstreetreporter.com/2022/03/31/next-super-stock-pharmadrug-otc-lmllf-cse-phrx-advancing-biopharm-assets-w-billion-dollar-markets/
NexTech AR (OTC: NEXCF) (CSE: NTAR) CEO Evan Gappelberg: “NexTech is On-Ramp to Metaverse & Web 3.0 for $5.5 Trillion E-Commerce Market”
NexTech AR (OTC: NEXCF), a featured presenter at Wall Street Reporter's "Next Super Stock" investor conference series, recently shared with investors how NEXCF is emerging as a key player in the $5.5 trillion global e-commerce market transition to web 3.0 and the metaverse. NEXCF Augmented Reality solutions enable to view products in lifelike 3D, in their own living room. This AR shopping experience bridges the gap between the physical world, and what was once a flat 2D online e-commerce experience. NEXCFs AR shopping experience is a “game changer” for the 5.5 trillion global e-commerce industry (source: Statisa 2022).
Watch NEXT SUPER STOCK (OTC: NEXCF) (CSE: NTAR) Video: https://www.wallstreetreporter.com/2022/04/06/next-super-stock-nextech-ar-otc-nexcf-cse-ntar-on-ramp-to-metaverse-web-3-0-for-5-trillion-e-commerce-market/
NEXCF AR solutions create billions of dollars in potential profitability and cost cost-savings for e-commerce leaders by driving +93% increases in click through rate, and -40% reductions in product returns. This value creation and ROI is driving growing demand and industry adoption of NEXCF AR solutions. Nearly 2 billion of the world’s population now shops online. Most importantly, over 72% of e-commerce is now done by mobile phone - a native platform for Augemented Reality apps like NEXCF. Global blue chip brands utilizing NexTech AR, include: Ford Mach EV, Kohls, CB2, Crate & Barrel, Pier 1, and Segway.
“NexTech’s AR solutions are rapidly becoming a ‘must-have’ for e-commerce leaders to succeed in today’s hyper-competitive market, where even marginal improvements in metrics like click-though and return-rates can mean the difference of billions of dollars to a company’s bottom line…We’re at an inflection point now, where industry demand and adoption for NexTech’s AR is accelerating and going mainstream. As E-Commerce shifts to Web 3.0 and the Metaverse, the demand for AR/3D product models becomes essential. NexTech is emerging as the “on ramp” to the Metaverse and Web 3.0 for the $5.5 trillion e-commerce industry. With over 200 million product SKU’s in e-commerce worldwide - NexTech has a potential revenue pipeline worth billions of dollars in coming years.”
Watch NEXT SUPER STOCK (OTC: NEXCF) (CSE: NTAR) Video: https://www.wallstreetreporter.com/2022/04/06/next-super-stock-nextech-ar-otc-nexcf-cse-ntar-on-ramp-to-metaverse-web-3-0-for-5-trillion-e-commerce-market/
April 19 - NEXCF launches BigCommerce App For 3D Model Making. With this App going live, Nextech’s ARitize 3D SaaS offering for ecommerce, extends the Company's 3D model creation capabilities to BigCommerce merchants. This App seamlessly provides BigCommerce merchants with the software needed to sell effectively online, with a frictionless one click integration for 3D model making. Nextech has already integrated with Shopify earlier this year, and will integrate with WooCommerce within the next 30 days. As demand for 3D models rises exponentially, the Company also plans to partner with Magento and other ecommerce platforms throughout 2022, continuing to rollout its third party SaaS integration and providing its ARitize 3D modelling solution to millions of ecommerce merchants globally.
April 14 - NEXCF launches Nextech Metaverse Suite. This Suite of Metaverse SaaS products unifies Nextech’s entire technology stack of 3D and AR products and apps into one, end-to-end seamless and easy to use SaaS subscription based platform.Nextech views SaaS as a significant advancement of all its 3D modelling and augmented reality solutions. SaaS integration has enormous implications for scalability and the company's future revenue growth.
April 12 - NEXCF launches Shopify “freemium” 3D model pricing, updating the Company’s Shopify app, initially launched in January, allowing merchants to create 3D/AR models for their ecommerce site.
April 6 - NEXCF files four pivotal non-provisional utility patents with respect to its Aritize 3D and ARitize CAD products for 3D model making, further strengthening the Company’s intellectual property position.
Watch NEXT SUPER STOCK (OTC: NEXCF) (CSE: NTAR) Video: https://www.wallstreetreporter.com/2022/04/06/next-super-stock-nextech-ar-otc-nexcf-cse-ntar-on-ramp-to-metaverse-web-3-0-for-5-trillion-e-commerce-market/
ORAGIN Foods (OTC: OGGFF) (TSX.V: OG) CEO Matt Lurie: “Ready to Scale with Plant-Based Brands and Next Gen Organic Retailing”
ORAGIN Foods (OTC: OGGFF) a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK investor conference, is capitalizing on twin megatrends in the booming plant-based foods space and specialty organic retailing. In his recent presentation, OGGFF CEO Matt Lurie shared with investors how OGGFF is positioned for explosive growth in the coming months, as it scales its “Organic Garage” specialty retail stores and expands its portfolio of CPG brands focusing on the the plant-based and organic lifestyle.
Watch ORAGIN Foods (OTC: OGGFF) (TSX: OG) Next Super Stock livestream video:https://www.wallstreetreporter.com/2022/03/01/oragin-foods-otc-oggff-tsx-og-unleashes-30x-upside-potential/
OGGFF’s “Organic Garage” specialty retail stores have built up a cult following among millennial shoppers in Toronto, Canada through a fun experiential retail concept and discount pricing - “Healthier Food For Less”. OGGFF currently has four stores generating over $30 million in revenue, at strong gross margins - and is now at an inflection point - ready to scale rapidly with new locations. In his interview with Wall Street Reporter, OGGFF CEO Matt Lurie discusses the possibilities for scaling the Organic Garage brand globally, whether through company owned stores, partnerships, and or franchises.
CEO Matt Lurie is especially excited about the growth potential for OGGFF’s branded CPG (Consumer Packaged Goods) business focused on the $30 billion plant-based foods and lifestyle sector. OGGFF is leveraging its retailing domain expertise into the plant-based foods space. With a strong insight and data on what sells on retail shelves and what today’s consumers want, OGGFF is developing a suite of plant-based CPG brands through acquisitions, and internal development with a significant focus on expansion in the US market.
One of OGGFF’s recently launched CPG brands “Future of Cheese” (targeting the $900 billion dairy alternatives market) is already gaining significant traction. Developed by the world’s leading cheese experts, Future of Cheese is rolling out a full line of cheese, butter and other exciting plant-based dairy products. The brand is a hit with consumers and products are selling out on shelves weekly. OGGFF is now expanding its product portfolio to 8-10 SKU’s in coming months which will help drive market penetration with international retailers, and restaurants. OGGFF expects significant revenue growth potential as it further develops a diversified suite of synergistic CPG brands through acquisitions in coming months.
Watch ORAGIN Foods (OTC: OGGFF) (TSX: OG) Next Super Stock livestream video:https://www.wallstreetreporter.com/2022/03/01/oragin-foods-otc-oggff-tsx-og-unleashes-30x-upside-potential/
Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, M.D.: “Nova’s Psilocybin-based Therapeutics Showing Vast Potential for Autism and Other Neuroinflammatory Disorders”
Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK investor conference is advancing psilocybin-based novel therapeutics, targeting autism spectrum disorders, an unmet medical need with multi-billion dollar market potential. NMLSF Chief Medical Officer Dr. Marvin Hausman, M.D., has a decades-long track record of success advancing new drugs through the FDA regulatory pathways, into commercialization, generating billions of dollars in revenue. Dr. Hausman, is now bringing the “same playbook” to NMLSF for its psilocybin-based therapeutics targeting Fragile X, then potential expansion to treat other neuroinflammatory disorders, including alzheimers, and parkinsons. NMLSF plans to submit a clinical trial application to Health Canada for a Phase 2A study evaluating its psilocybin microdose therapy for Fragile X Syndrome, in the coming weeks.
NMLSF is a global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. NMLSF is the first biotech company to achieve FDA “Orphan Drug Designation” in both the United States and European Union for the use of psilocybin in the treatment of FXS. In his interview, with Wall Street Reporter, Dr. Hausman explains his strategy for advancing NMLSF’s drug pipeline through commercialization, as he has successfully accomplished with other novel drugs during his decades-long career.
Watch NEXT SUPER STOCK Nova Mentis (OTC: NMLSF) (CSE: NOVA) Video: https://www.wallstreetreporter.com/2022/03/25/next-super-stock-nova-mentis-life-sciences-otc-nmlsf-billions-opportunity-w-autism-psilocybin/
"The recently completed preclinical study of repeat low doses of our psilocybin drug - every other day for 2 weeks, showed clinical responses that greatly exceeded our expectations. We significantly modulated behavioural and cognitive defects, such as recognition memory, in FXS." NMLSF plans to submit a clinical trial application to Health Canada in the coming weeks for a Phase 2A study evaluating psilocybin microdose therapy for FXS. "Autism spectrum disorder ("ASD") and especially FXS, the largest genetic cause of ASD, continue to have unmet medical needs. Scientists at NOVA, over the past two years, have laid the groundwork for development of potential novel psilocybin-based microdose treatment of ASD," said NMLSF Chief Medical Officer, Dr. Marvin S. Hausman, MD.
April 8 - NMLSF contracts with Toronto Institute of Pharmaceutical Technology to formulate and manufacture psilocybin microdose capsules for its upcoming Canadian Phase 2A fragile X syndrome clinical study. NMLSF has already manufactured a large supply of >98% pure psilocybin for clinical studies and commercialization following drug approval.
March 23 - NMLSF begins patient enrollment process for its North American Observational study: Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS). NMLSF’s Observational Study will study the neuroinflammatory mRNA genetic profile contained within cheek cells from ASD and FXS patients, as well as measure serotonin levels in patient saliva. The research objective is to develop a genetic neuroinflammatory and serotonin data bank that will help establish a "Diagnostic Index" – an objective set of tools that helps to differentiate subtypes of ASD, as well as FXS, and to develop more accurate methods of diagnosis and treatment. Collected data will be analyzed using customized machine learning algorithms and used to guide design of upcoming clinical trials that will test the efficacy of psilocybin-based therapeutics in ASD and FXS. Patients enrolled in this Observational Study will have a high priority position to be enrolled in planned psilocybin microdose clinical trials in Canada and the United States. NOVA is aiming to recruit at least 300 qualifying participants; 200+ ASD/FSX patients and 100+ neurotypical controls. Patient enrollment information at: novamentis.ca/autismstudy
"Families caring for patients with autism spectrum disorder (ASD) and fragile X syndrome (FXS) deserve new scientific and therapeutic options to improve diagnosis, quality of care and treatment outcomes. The goal of our North American ASD and FXS Observational Study is to uncover novel and meaningful ways to diagnose and treat ASD and FXS, which is particularly relevant for statistical separation between the multitude of ASD subtypes, currently differentiated rather crudely, based on behavioural analysis," says NMLSF Chief Medical Officer, Dr. Marvin S. Hausman MD.
February 16 - NMLSF successfully completes an oral microdose psilocybin preclinical study, in the laboratory of Dr. Viviana Trezza, Rome Tre University, Rome, Italy. The results exceeded all expectations with the findings that a very low dose of the Company's proprietary psilocybin significantly modulated behavioural and cognitive defects, such as recognition memory, in a genetic model of fragile X syndrome (FXS). "The science team led by Dr. Hausman, together with Dr. Viviana Trezza from Roma Tre University, continues to deliver promising preclinical results. The recent oral microdose data set not only confirms but exceeds our original injectable formulation results," says Will Rascan, CEO of NOVA. "The clear positive data is critical as we prepare to submit our clinical trial application to Health Canada for a Phase 2A study evaluating psilocybin microdose therapy for fragile X syndrome."
Watch NEXT SUPER STOCK Nova Mentis (OTC: NMLSF) (CSE: NOVA) Video: https://www.wallstreetreporter.com/2022/03/25/next-super-stock-nova-mentis-life-sciences-otc-nmlsf-billions-opportunity-w-autism-psilocybin/
PharmaDrug (OTC: LMLLF) (CSE: PHRX) CEO Dan Cohen: “Advancing Drug Pipeline Addressing Billion Dollar Markets”
PharmaDrug (OTC: LMLLF) (CSE: PHRX) CEO Dan Cohen, a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK investors conference is advancing a pipeline of natural based drugs, addressing multi-billion dollar market opportunities in cancers, anti-viral and glaucoma indications. LMLLF now has four drug candidates advancing towards clinical trials, with key milestones in the weeks ahead.
Watch NEXT SUPER STOCK PharmaDrug (OTC: LMLLF) (CSE: PHRX) Video: https://www.wallstreetreporter.com/2022/03/31/next-super-stock-pharmadrug-otc-lmllf-cse-phrx-advancing-biopharm-assets-w-billion-dollar-markets/
LMLLF’s flagship platform is PD-001 – a reformulated and patented version of cepharanthine, with lab data demonstrating potential therapies for a number of anti-cancer and anti-viral indications. Cephrantine is a natural based drug already approved in Japan, with a 70 year history of use. Cepharanthine has shown in studies to both stop the spread and kill cancer cells, and reduce resistance to chemotherapy.
LMLLF’s PD-001 is a reformulation of the traditional treatment in pill form used in Japan, but with 10X the bioavailability. LMLLF sees its PD-001 as a platform for potentially treating a wider array of cancer indications.
LMLLF is now advancing studies for PD-001 for treating esophageal, and prostate cancers. LMLLF has just received FDA Orphan Drug Designation for PD-001 for esophageal cancer a $1.5 billion market opportunity. Orphan Drug Designation allows for potentially fast track FDA approval, lower development costs and increased market protection. LMLLF is also advancing PD-001 for prostate cancer, filing a provisional patent for cepharanthine combined with chemo for prostate cancer.
LMLLF is also developing a treatment for glaucoma, based on a re-formulation of DMT (N-Dimethyltryptamine) to reduce intraocular pressure. Tryptamines, including DMT, have been shown in clinical studies to reduce intraocular pressure. LMLLF is collaborating with the Terasaki Institute for Biomedical Innovation, a world class leader in development of novel drug delivery technologies to optimize DMT formulation with a controlled release device. LMLLF’s clinical research has developed two potential drug formulations, which have have tested well for low toxicity, and show promising potency and efficacy, and expects to initiate FDA clinical trials in coming months. In his interview, CEO Dan Cophen also shares that LMLLF’s pipeline assets have significant upside potential as biotech valuations recover from current cyclical lows.
April 19 - LMLLF expands IP portfolio assets, filing a second provisional patent application to support new claims specifically related to the in vivo dosing of cepharanthine in combination with taxane-family members for the treatment of prostate cancer. The current patent application aims to complement the previous provisional patent filing, built around the Company's in vitro study findings, which set forth claims related to the use of cepharanthine plus cabazitaxel and/or other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancer.
April 7 - LMLLF advances DMT-analogue program for glaucoma with production of medical device designed to provide sustained control of elevated intraocular pressure, in collaboration with the Terasaki Institute for Biomedical Innovation
March 9 - LMLLF reports positive interim findings for combination of Cepharanthine and frontline chemotherapy for IND-enabling prostate cancer study.The study demonstrated improved tumor growth inhibition by 73% compared to cabazitaxel-alone.
Watch NEXT SUPER STOCK PharmaDrug (OTC: LMLLF) (CSE: PHRX) Video: https://www.wallstreetreporter.com/2022/03/31/next-super-stock-pharmadrug-otc-lmllf-cse-phrx-advancing-biopharm-assets-w-billion-dollar-markets/
WALL STREET REPORTER
Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. www.WallStreetReporter.com. Nothing in this news summary shall be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer, and relevant SEC 17B disclosures here: https://tinyurl.com/2x4eznd5
About Wall Street Reporter’s Next Super Stock conference:
Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/
CONTACT:
WALL STREET REPORTER
(212) 871-2057 ext 7
